{
  
  "drug_data": [
    {
      "drug_name": "Adalimumab (Humira)",
      "competitors": "Amjevita",
      "open_source": "FDA",
      "news_topic": "Humira's resilience in the face of biosimilar competition",
      "source": "Clarivate",
      "source_link": "https://clarivate.com/academia-government/lp/humira-survives-competition-from-adalimumab-biosimilars-for-now/",
      "news_date": "2024-07-30",
      "summary": "Despite the availability of nine lower-priced rival products in the US, AbbVie's Humira (adalimumab) has retained more than 80% of patients over the past year.",
      "last_updated_date": "2025-02-02"
    },
    {
      "drug_name": "Adalimumab (Humira)",
      "competitors":  "Hadlima",
      "open_source": "FDA",
      "news_topic": "Humira's resilience in the face of biosimilar competition",
      "source": "Clarivate",
      "source_link": "https://clarivate.com/academia-government/lp/humira-survives-competition-from-adalimumab-biosimilars-for-now/",
      "news_date": "2024-07-30",
      "summary": "Despite the availability of nine lower-priced rival products in the US, AbbVie's Humira (adalimumab) has retained more than 80% of patients over the past year.",
      "last_updated_date": "2025-02-02"
    },
    {
      "drug_name": "Etanercept (Enbrel)",
      "competitors": "Erelzi",
      "open_source": "EMA",
      "news_topic": "Biosimilars of Enbrel",
      "source": "FDA",
      "source_link": "https://www.fda.gov/drugs/biosimilars/biosimilar-product-information",
      "news_date": "2024-06-15",
      "summary": "The FDA has approved biosimilars for Enbrel, including Erelzi and Eticovo, offering more treatment options for patients.",
      "last_updated_date": "2025-02-02"
    },
    {
      "drug_name": "Infliximab (Remicade)",
      "competitors": "Inflectra",
        
      "open_source": "Clinical Trials",
      "news_topic": "Biosimilars of Remicade",
      "source": "FDA",
      "source_link": "https://www.fda.gov/drugs/biosimilars/biosimilar-product-information",
      "news_date": "2024-05-20",
      "summary": "Several biosimilars for Remicade have been approved by the FDA, including Inflectra, Renflexis, Ixifi, and Avsola.",
      "last_updated_date": "2025-02-02"
    },
    {
      "drug_name": "Tocilizumab (Actemra)",
      "competitors":"RoActemra",
      "open_source": "EMA",
      "news_topic": "Actemra's role in COVID-19 treatment",
      "source": "EMA",
      "source_link": "https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra",
      "news_date": "2024-08-10",
      "summary": "Actemra (tocilizumab) has been authorized for the treatment of severe COVID-19 in hospitalized patients.",
      "last_updated_date": "2025-02-02"
    },
    {
      "drug_name": "Secukinumab (Cosentyx)",
      "competitors": 
        "Taltz",
        
      "open_source": "Google Search",
      "news_topic": "Cosentyx approved for new indications",
      "source": "FDA",
      "source_link": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-uses-cosentyx",
      "news_date": "2024-09-05",
      "summary": "The FDA has approved new indications for Cosentyx (secukinumab), expanding its use to additional inflammatory conditions.",
      "last_updated_date": "2025-02-02"
    },
    {
      "drug_name": "Secukinumab (Cosentyx)",
      "competitors": "Siliq", 
      "open_source": "Google Search",
      "news_topic": "Cosentyx approved for new indications",
      "source": "FDA",
      "source_link": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-uses-cosentyx",
      "news_date": "2024-09-05",
      "summary": "The FDA has approved new indications for Cosentyx (secukinumab), expanding its use to additional inflammatory conditions.",
      "last_updated_date": "2025-02-02"
    }
  ]

}
  